XML 71 R55.htm IDEA: XBRL DOCUMENT
v3.22.4

Research & Development ("R&D") Funding Expense (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Research and development funding expense | $ 177,106 | $ 200,084 | $ 26,289
Upfront payment and premium paid |  | 193,200 |
Merck to Fund |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Research and development funding expense | 50,000 |  |
Cytokinetics |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Research and development funding expense | 100,000 |  |
Theravance Biopharma |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Research and development funding expense | $ 25,000 |  |
Funding Agreements With Sanofi |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Research and development funding expense |  | 6,900 | 20,500
MorphoSys |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Research and development funding expense |  | 90,000 |
MorphoSys | BioCryst Pharmaceuticals, Inc. |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Research and development funding expense |  | $ 103,200 |
Funding Agreement With BioCryst |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |
Research and development funding expense |  |  | $ 5,800

X
- Definition Research and Development Expense, Upfront Payment and Premium Paid + References No definition available. + Details
Name: | rprx_ResearchAndDevelopmentExpenseUpfrontPaymentAndPremiumPaid
Namespace Prefix: | rprx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rprx_MerckToFundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rprx_CytokineticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rprx_TheravanceBiopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rprx_FundingAgreementsWithSanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rprx_MorphoSysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=rprx_BioCrystPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rprx_FundingAgreementWithBioCrystMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |